JP2024539273A - Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 - Google Patents

Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 Download PDF

Info

Publication number
JP2024539273A
JP2024539273A JP2024524598A JP2024524598A JP2024539273A JP 2024539273 A JP2024539273 A JP 2024539273A JP 2024524598 A JP2024524598 A JP 2024524598A JP 2024524598 A JP2024524598 A JP 2024524598A JP 2024539273 A JP2024539273 A JP 2024539273A
Authority
JP
Japan
Prior art keywords
tcr
polypeptide
cells
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539273A5 (https=
JPWO2023076863A5 (https=
Inventor
カシアン イー
ケ パン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2024539273A publication Critical patent/JP2024539273A/ja
Publication of JP2024539273A5 publication Critical patent/JP2024539273A5/ja
Publication of JPWO2023076863A5 publication Critical patent/JPWO2023076863A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024524598A 2021-10-25 2022-10-24 Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 Pending JP2024539273A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163271368P 2021-10-25 2021-10-25
US63/271,368 2021-10-25
US202163279527P 2021-11-15 2021-11-15
US63/279,527 2021-11-15
PCT/US2022/078597 WO2023076863A2 (en) 2021-10-25 2022-10-24 Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use

Publications (3)

Publication Number Publication Date
JP2024539273A true JP2024539273A (ja) 2024-10-28
JP2024539273A5 JP2024539273A5 (https=) 2025-10-31
JPWO2023076863A5 JPWO2023076863A5 (https=) 2025-10-31

Family

ID=86158936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524598A Pending JP2024539273A (ja) 2021-10-25 2022-10-24 Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法

Country Status (4)

Country Link
EP (1) EP4422651A4 (https=)
JP (1) JP2024539273A (https=)
CA (1) CA3236237A1 (https=)
WO (1) WO2023076863A2 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100564T1 (it) * 2016-04-08 2022-01-10 Adaptimmune Ltd Recettori di cellule t
AU2018318303A1 (en) * 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
BR112021025548A2 (pt) * 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
WO2021236548A1 (en) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use

Also Published As

Publication number Publication date
EP4422651A4 (en) 2025-12-17
WO2023076863A2 (en) 2023-05-04
WO2023076863A3 (en) 2023-06-15
CA3236237A1 (en) 2023-05-04
EP4422651A2 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
JP7785696B2 (ja) 操作されたｔ細胞受容体および使用の方法
JP2023548556A (ja) Ｅｇｆｒ抗原を標的とする操作されたｔ細胞受容体および使用方法
JP2024539291A (ja) 神経膠芽腫を治療するための方法および組成物
JP7827645B2 (ja) 操作されたｔ細胞受容体および使用の方法
TWI893070B (zh) 經工程化之t細胞受體及使用方法
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
JP2024539273A (ja) Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
WO2026019786A1 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
CN118302176A (zh) 靶向mage-a4抗原的肽和经改造t细胞受体及使用方法
CN117425482A (zh) 靶向egfr抗原的经改造t细胞受体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251023